RNA interference therapy via functionalized scaffolds
- PMID: 21241760
- DOI: 10.1016/j.addr.2011.01.006
RNA interference therapy via functionalized scaffolds
Abstract
Tissue engineering aims to provide structural and biomolecular cues to compromised tissues through scaffolds. An emerging biomolecular cue is that of RNA interference by which the expression of genes can be silenced through a potent endogenous pathway. Recombinant viral-based approaches in RNAi delivery exist; however non-viral strategies offer many opportunities to exploit this mechanism of regulation in a safer way. Current RNAi therapies in clinical trials are without a vector (naked) or have slightly modified structures. Modification of these molecules with efficient backbone moieties for improved stability and potency, protecting and buffering them with delivery vehicles, and using scaffolds as reservoirs of delivery is at the frontier of current research. However, to enable an efficient sustained therapeutic effect scaffolds have a potentially significant role to play. This review presents non-viral delivery of RNAi that have been attempted via tissue engineered scaffolds. For RNAi to have a clinical impact, it is imperative to evaluate optimal delivery systems to ensure that the efficacy of this promising technology can be maximized.
Copyright © 2011 Elsevier B.V. All rights reserved.
Similar articles
-
Viral vector-mediated RNA interference.Curr Opin Pharmacol. 2010 Oct;10(5):534-42. doi: 10.1016/j.coph.2010.06.007. Epub 2010 Jul 9. Curr Opin Pharmacol. 2010. PMID: 20620113 Review.
-
Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials.Early Hum Dev. 2009 Oct;85(10 Suppl):S31-5. doi: 10.1016/j.earlhumdev.2009.08.013. Epub 2009 Oct 14. Early Hum Dev. 2009. PMID: 19833462
-
Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.Adv Drug Deliv Rev. 2007 Mar 30;59(2-3):164-82. doi: 10.1016/j.addr.2007.03.010. Epub 2007 Mar 21. Adv Drug Deliv Rev. 2007. PMID: 17481774 Review.
-
Efficient and targeted delivery of siRNA in vivo.FEBS J. 2010 Dec;277(23):4814-27. doi: 10.1111/j.1742-4658.2010.07904.x. FEBS J. 2010. PMID: 21078116 Review.
-
Nonviral in vivo delivery of therapeutic small interfering RNAs.Curr Opin Mol Ther. 2007 Aug;9(4):345-52. Curr Opin Mol Ther. 2007. PMID: 17694447 Review.
Cited by
-
Biomaterial-mediated modification of the local inflammatory environment.Front Bioeng Biotechnol. 2015 May 15;3:67. doi: 10.3389/fbioe.2015.00067. eCollection 2015. Front Bioeng Biotechnol. 2015. PMID: 26029692 Free PMC article. Review.
-
Dendrimers for siRNA Delivery.Pharmaceuticals (Basel). 2013 Feb 4;6(2):161-83. doi: 10.3390/ph6020161. Pharmaceuticals (Basel). 2013. PMID: 24275946 Free PMC article.
-
Effects of CD25siRNA gene transfer on high-risk rat corneal graft rejection.Graefes Arch Clin Exp Ophthalmol. 2015 Oct;253(10):1765-76. doi: 10.1007/s00417-015-3067-2. Epub 2015 May 31. Graefes Arch Clin Exp Ophthalmol. 2015. PMID: 26024991
-
Photocleavable Hydrogels for Light-Triggered siRNA Release.Adv Healthc Mater. 2016 Feb 4;5(3):305-310. doi: 10.1002/adhm.201500778. Epub 2015 Dec 7. Adv Healthc Mater. 2016. PMID: 26639103 Free PMC article.
-
Sustained delivery of siRNA/PEI complex from in situ forming hydrogels potently inhibits the proliferation of gastric cancer.J Exp Clin Cancer Res. 2016 Mar 31;35:57. doi: 10.1186/s13046-016-0334-y. J Exp Clin Cancer Res. 2016. PMID: 27029190 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources